학술논문
Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
Document Type
article
Author
Source
Journal of Personalized Medicine, Vol 11, Iss 11, p 1190 (2021)
Subject
Language
English
ISSN
2075-4426
Abstract
The treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) is a highly unmet medical need. The classic treatment approach for these patients—androgen deprivation therapy (ADT) alone—until metastatic progression is now considered suboptimal. Several randomized phase III clinical trials have demonstrated significant clinical benefits—including significantly better overall survival (OS)—for treatments that combine ADT with apalutamide, enzalutamide, and darolutamide. As a result, these approaches are now included in treatment guidelines and are considered a standard of care. In the present article, we discuss the changing landscape of the management of patients with nmCRPC.